Fully-integrated, component-based CDMS offers flexibility, customization, and efficiency.
Exploring the different stages in the development of a digital measure, and the activities and steps key to achieving meaningful impact for patients.
Five therapeutic areas that are apt for an all-virtual approach, and that can serve as an entry point for sponsors who are hesitant yet interested in exploring the growing DCT model.
The data, not the plan, provide the direction.
Whether unstructured patient diaries will be part of future clinical trials depends on three main factors, including answers around added value.
2020 Tufts CSDD study examines relationship between investigative site personnel diversity and study participant diversity.
How industry can increase the speed of these trials while continuing to meet patient needs.
Eliminating barriers to engage underrepresented populations.
Amid CVS’ surprise exit from the clinical research space and the ensuing broader questions, study investigates the benefits of pharmacy chain involvement—along with the concerns and barriers to adoption.
Sites not expected to fade away even as DCTs continue to grow past COVID-19.
This article highlights how C2N Diagnostics and Firma Clinical Research teamed up to create a successful Alzheimer's diagnostic clinical trial while allowing participants to remain in their homes.
Recent study results highlight need for new metrics in ECOG scoring to mitigate variability.
Data validation, consistent communication, and meticulous documentation all keys to successfully switching CROs.
Bayesian methods bring flexibility and speed to clinical trial design and analysis, and with increased access to the necessary computational power, are transforming today’s clinical research.
Pilot study seeks to validate new and more granular outsourcing model classifications in differentiating performance across custom contract-service approaches.
***Live: Monday, December 7, 2020 at 2pm EST | 1pm CST | 11am PST***Discover how a North American pharmaceutical company succeeded where dozens of trial sponsors had failed. Leveraging innovative new clinical software, the company helped transition its breakthrough science into trial success, by delivering consistently impeccable data that accelerated the program with far less cost and effort – ultimately leading to a successful submission***On demand available after final airing until Dec. 7, 2021***
Digitalization has revolutionized an industry once reliant on paper collection.
A novel adaptive-block method of randomization to maximize the efficiency of overall treatment group balance, while maintaining balance at investigational centers in smaller sized studies, is proposed.
Sponsors and CROs can ease the burdens of patients, sites, and physicians by identifying these 3 key areas.
AI can also help reduce waste from 70% to 25%.
The data, not the plan, provide the direction.
The emergence of AI-powered simulants in improving study efficiency.
Improving clinical trial diversity and health equity through strategic collaborations.
The four new methodological Patient-Focused Drug Development guidance documents the FDA is currently developing for the industry that incorporate patient experience data into drug development, summarized.
Cloud-based clinical metadata repositories can aid in accelerating clinops.
Founded in 2015, Decibel is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance. For this growth-stage biotech, Egnyte has been a valuable partner in supporting clinical and regulatory operations, medical writing, biostatistics and data management teams with a single repository for all documentation gathered from CROs and submitted to the FDA and other regulatory agencies.
Utilizing a broad network of provider sites is key in overcoming failure and enabling access to high quality data.
Pandemic sparks new long-term plan for success in R&D.